One-year direct and indirect costs of ischaemic stroke in China.

IF 2.6 1区 医学
Wei Lv, Anxin Wang, Qianyi Wang, Ruimin Wang, Qin Xu, Shuqing Wu, Yi Han, Yong Jiang, Jinxi Lin, Jing Jing, Hao Li, Yongjun Wang, Xia Meng
{"title":"One-year direct and indirect costs of ischaemic stroke in China.","authors":"Wei Lv, Anxin Wang, Qianyi Wang, Ruimin Wang, Qin Xu, Shuqing Wu, Yi Han, Yong Jiang, Jinxi Lin, Jing Jing, Hao Li, Yongjun Wang, Xia Meng","doi":"10.1136/svn-2023-002296","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>This is the first real-world study to estimate the direct costs and indirect costs of first-ever ischaemic stroke with 1-year follow-up in China, based on a nationally representative sample.</p><p><strong>Methods: </strong>Patients were chosen from 20 geographically diverse sites from the nationally representative database China National Stroke Registry-III (CNSR-III). The inclusion criteria were surviving patients who were hospitalised with first-ever ischaemic stroke from February 2017 to February 2018 (the index event); aged 18-80 during the index event; no history of other stroke types. The primary endpoints were direct medical costs, direct non-medical costs, indirect costs and total cost (ie, the sum of all cost components). Patient characteristics and clinical data were extracted from CNSR-III. Stroke-related in-hospital direct medical costs were collected from hospital electronic medical records. The patient survey collected data related to out-of-hospital direct medical costs, direct non-medical costs and indirect costs. The secondary objective was to explore clinical factors associated with cost outcomes through univariate analysis and multiple regression.</p><p><strong>Results: </strong>The study enrolled 520 patients. The total cost was 57 567.48 CNY, with 26 612.67 CNY direct medical costs, 2 787.56 CNY direct non-medical costs and 28 167.25 CNY indirect costs. Univariate analysis showed that longer lengths of stay during the index event, higher National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale scores were associated with higher costs in all categories. Conversely, EuroQol 5 Dimension utility scores were associated with decreased costs except direct non-medical costs. Multiple regressions showed that higher admission NIHSS scores were independently associated with higher direct medical costs, indirect costs and total cost. Higher 3-month utilities were associated with lower total cost.</p><p><strong>Conclusion: </strong>This real-world study showed substantial 1-year economic burden following first-ever ischaemic stroke in China, and that indirect costs are a non-negligible driver of costs.</p>","PeriodicalId":48733,"journal":{"name":"Journal of Investigative Medicine","volume":null,"pages":null},"PeriodicalIF":2.6000,"publicationDate":"2024-08-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Investigative Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1136/svn-2023-002296","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: This is the first real-world study to estimate the direct costs and indirect costs of first-ever ischaemic stroke with 1-year follow-up in China, based on a nationally representative sample.

Methods: Patients were chosen from 20 geographically diverse sites from the nationally representative database China National Stroke Registry-III (CNSR-III). The inclusion criteria were surviving patients who were hospitalised with first-ever ischaemic stroke from February 2017 to February 2018 (the index event); aged 18-80 during the index event; no history of other stroke types. The primary endpoints were direct medical costs, direct non-medical costs, indirect costs and total cost (ie, the sum of all cost components). Patient characteristics and clinical data were extracted from CNSR-III. Stroke-related in-hospital direct medical costs were collected from hospital electronic medical records. The patient survey collected data related to out-of-hospital direct medical costs, direct non-medical costs and indirect costs. The secondary objective was to explore clinical factors associated with cost outcomes through univariate analysis and multiple regression.

Results: The study enrolled 520 patients. The total cost was 57 567.48 CNY, with 26 612.67 CNY direct medical costs, 2 787.56 CNY direct non-medical costs and 28 167.25 CNY indirect costs. Univariate analysis showed that longer lengths of stay during the index event, higher National Institutes of Health Stroke Scale (NIHSS) and modified Rankin Scale scores were associated with higher costs in all categories. Conversely, EuroQol 5 Dimension utility scores were associated with decreased costs except direct non-medical costs. Multiple regressions showed that higher admission NIHSS scores were independently associated with higher direct medical costs, indirect costs and total cost. Higher 3-month utilities were associated with lower total cost.

Conclusion: This real-world study showed substantial 1-year economic burden following first-ever ischaemic stroke in China, and that indirect costs are a non-negligible driver of costs.

中国缺血性脑卒中一年的直接和间接费用。
背景:这是第一项基于全国代表性样本对中国首次缺血性中风的直接成本和间接成本进行1年随访的真实世界研究。方法:从具有全国代表性的数据库中国卒中登记III(CNSR-III)中选择20个地理位置不同的患者。纳入标准为2017年2月至2018年2月因首次缺血性中风住院的存活患者(指标事件);指数事件期间18-80岁;没有其他中风类型的病史。主要终点是直接医疗成本、直接非医疗成本、间接成本和总成本(即所有成本组成部分的总和)。从CNSR-III中提取患者特征和临床数据。从医院电子医疗记录中收集与中风相关的住院直接医疗费用。患者调查收集了与院外直接医疗费用、直接非医疗费用和间接费用有关的数据。次要目的是通过单因素分析和多元回归探讨与成本结果相关的临床因素。结果:本研究纳入520名患者。总费用为57 567.48元,其中直接医疗费用26 612.67元,直接非医疗费用2 787.56元,间接费用28 167.25元。单变量分析显示,指数事件期间停留时间越长,美国国立卫生研究院卒中量表(NIHSS)和改良兰金量表得分越高,所有类别的费用都越高。相反,除直接非医疗成本外,EuroQol 5维度效用得分与成本降低有关。多元回归显示,入院NIHSS评分越高,直接医疗费用、间接费用和总费用就越高。3个月的公用事业费用较高,总成本较低。结论:这项真实世界的研究表明,中国首次缺血性中风后1年的经济负担相当大,间接成本是成本的一个不可忽视的驱动因素。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Investigative Medicine
Journal of Investigative Medicine MEDICINE, GENERAL & INTERNALMEDICINE, RESE-MEDICINE, RESEARCH & EXPERIMENTAL
自引率
0.00%
发文量
111
期刊介绍: Journal of Investigative Medicine (JIM) is the official publication of the American Federation for Medical Research. The journal is peer-reviewed and publishes high-quality original articles and reviews in the areas of basic, clinical, and translational medical research. JIM publishes on all topics and specialty areas that are critical to the conduct of the entire spectrum of biomedical research: from the translation of clinical observations at the bedside, to basic and animal research to clinical research and the implementation of innovative medical care.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信